EDG-7500

DRUG5 trials

Sponsors

Edgewise Therapeutics, Inc.

Conditions

Healthy Adult ParticipantsHealthy SubjectsHepatic Impairment (HI)Hypertrophic CardiomyopathyRenal Impairments

Phase 1

A Study of EDG-7500 in Healthy Adults

CompletedNCT06011317

Edgewise Therapeutics, Inc.Healthy Subjects

Start: 2023-08-14End: 2024-06-20Updated: 2024-07-16

A Study to Evaluate EDG-7500 in People With Renal Impairment

CompletedNCT07034768

Edgewise Therapeutics, Inc.Renal Impairments

Start: 2025-07-22End: 2025-12-26Updated: 2026-03-12

A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

CompletedNCT07324616

Edgewise Therapeutics, Inc.Hepatic Impairment (HI)

Start: 2026-01-26End: 2026-04-07Updated: 2026-07-31

A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults

CompletedNCT07456059

Edgewise Therapeutics, Inc.Healthy Adult Participants

Start: 2026-03-10End: 2026-06-01Updated: 2026-07-31

Phase 2

A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)

Active, not recruitingNCT06347159

Edgewise Therapeutics, Inc.Hypertrophic Cardiomyopathy

Start: 2024-04-11End: 2027-12-01Target: 79Updated: 2026-07-31